One year of Nature Cancer

As we celebrate our first anniversary, we present a selection of articles we have published so far, highlighting key areas of our diverse scope.

Latest Issue

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR Open Access.
Our Open Access option complies with funder and institutional requirements.

Latest Research

  • Article |

    Ferrando and colleagues identify FYNTRAF3IP2 as a recurrent oncogenic gene fusion that promotes angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified through the activation of NF-κB signaling.

    • Christine S. Moon
    • , Clara Reglero
    • , Jose R. Cortes
    • , S. Aidan Quinn
    • , Silvia Alvarez
    • , Junfei Zhao
    • , Wen-Hsuan W. Lin
    • , Anisha J. Cooke
    • , Francesco Abate
    • , Craig R. Soderquist
    • , Claudia Fiñana
    • , Giorgio Inghirami
    • , Elias Campo
    • , Govind Bhagat
    • , Raul Rabadan
    • , Teresa Palomero
    •  & Adolfo A. Ferrando
  • Article |

    Garofano et al. use single-cell RNA-sequencing data to classify glioblastomas along a metabolic axis of mitochondrial and glycolytic/plurimetabolic states and a neurodevelopmental axis of proliferative/progenitor and neuronal states.

    • Luciano Garofano
    • , Simona Migliozzi
    • , Young Taek Oh
    • , Fulvio D’Angelo
    • , Ryan D. Najac
    • , Aram Ko
    • , Brulinda Frangaj
    • , Francesca Pia Caruso
    • , Kai Yu
    • , Jinzhou Yuan
    • , Wenting Zhao
    • , Anna Luisa Di Stefano
    • , Franck Bielle
    • , Tao Jiang
    • , Peter Sims
    • , Mario L. Suvà
    • , Fuchou Tang
    • , Xiao-Dong Su
    • , Michele Ceccarelli
    • , Marc Sanson
    • , Anna Lasorella
    •  & Antonio Iavarone
  • Article |

    Zhang and colleagues report that targeting GLS1 alleviates the glutamine dependence of ARID1A-mutated ovarian clear cell carcinomas, thereby suppressing their growth.

    • Shuai Wu
    • , Takeshi Fukumoto
    • , Jianhuang Lin
    • , Timothy Nacarelli
    • , Yemin Wang
    • , Dionzie Ong
    • , Heng Liu
    • , Nail Fatkhutdinov
    • , Joseph A. Zundell
    • , Sergey Karakashev
    • , Wei Zhou
    • , Lauren E. Schwartz
    • , Hsin-Yao Tang
    • , Ronny Drapkin
    • , Qin Liu
    • , David G. Huntsman
    • , Andrew V. Kossenkov
    • , David W. Speicher
    • , Zachary T. Schug
    • , Chi Van Dang
    •  & Rugang Zhang
  • Article |

    Pugh and colleagues use single-cell RNA sequencing, CRISPR screens and functional assays to define a gradient of developmental and wound-response cell states in glioblastoma stem cells, revealing insights into glioblastoma origins and potential therapeutic targets.

    • Laura M. Richards
    • , Owen K. N. Whitley
    • , Graham MacLeod
    • , Florence M. G. Cavalli
    • , Fiona J. Coutinho
    • , Julia E. Jaramillo
    • , Nataliia Svergun
    • , Mazdak Riverin
    • , Danielle C. Croucher
    • , Michelle Kushida
    • , Kenny Yu
    • , Paul Guilhamon
    • , Naghmeh Rastegar
    • , Moloud Ahmadi
    • , Jasmine K. Bhatti
    • , Danielle A. Bozek
    • , Naijin Li
    • , Lilian Lee
    • , Clare Che
    • , Erika Luis
    • , Nicole I. Park
    • , Zhiyu Xu
    • , Troy Ketela
    • , Richard A. Moore
    • , Marco A. Marra
    • , Julian Spears
    • , Michael D. Cusimano
    • , Sunit Das
    • , Mark Bernstein
    • , Benjamin Haibe-Kains
    • , Mathieu Lupien
    • , H. Artee Luchman
    • , Samuel Weiss
    • , Stephane Angers
    • , Peter B. Dirks
    • , Gary D. Bader
    •  & Trevor J. Pugh
  • Article |

    Mehta et al. show that PARP inhibition induces CSF1R-dependent immune-suppressive macrophages, and that its blockade restores PARP inhibitor efficacy and stimulates CD8+ T cell-dependent antitumor immunity in triple-negative breast cancer.

    • Anita K. Mehta
    • , Emily M. Cheney
    • , Christina A. Hartl
    • , Constantia Pantelidou
    • , Madisson Oliwa
    • , Jessica A. Castrillon
    • , Jia-Ren Lin
    • , Katie E. Hurst
    • , Mateus de Oliveira Taveira
    • , Nathan T. Johnson
    • , William M. Oldham
    • , Marian Kalocsay
    • , Matthew J. Berberich
    • , Sarah A. Boswell
    • , Aditi Kothari
    • , Shawn Johnson
    • , Deborah A. Dillon
    • , Mikel Lipschitz
    • , Scott Rodig
    • , Sandro Santagata
    • , Judy E. Garber
    • , Nadine Tung
    • , José Yélamos
    • , Jessica E. Thaxton
    • , Elizabeth A. Mittendorf
    • , Peter K. Sorger
    • , Geoffrey I. Shapiro
    •  & Jennifer L. Guerriero
  • Article |

    Westermann and colleagues define four subtypes of neuroblastoma based on super-enhancer profiles in primary patient samples, which could be linked to distinct clinical outcomes and cell identity characteristics.

    • Moritz Gartlgruber
    • , Ashwini Kumar Sharma
    • , Andrés Quintero
    • , Daniel Dreidax
    • , Selina Jansky
    • , Young-Gyu Park
    • , Sina Kreth
    • , Johanna Meder
    • , Daria Doncevic
    • , Paul Saary
    • , Umut H. Toprak
    • , Naveed Ishaque
    • , Elena Afanasyeva
    • , Elisa Wecht
    • , Jan Koster
    • , Rogier Versteeg
    • , Thomas G. P. Grünewald
    • , David T. W. Jones
    • , Stefan M. Pfister
    • , Kai-Oliver Henrich
    • , Johan van Nes
    • , Carl Herrmann
    •  & Frank Westermann

News & Comment

  • Editorial |

    This month marks one year since the launch of Nature Cancer. As we celebrate our first anniversary, we reflect on the past year and thank the cancer research community for embracing our journal.

  • Clinical Outlook |

    Inhibition of the anti-apoptotic protein BCL-2 has emerged as a highly effective treatment for acute myeloid leukemia; approved lower-intensity venetoclax combination therapies are now being rapidly incorporated into an improved standard of care for this cancer. Here we recount an abbreviated history of venetoclax for acute myeloid leukemia, focusing on a selection of key studies along the path from development into the clinic.

    • Courtney D. DiNardo
    •  & Marina Y. Konopleva
  • News & Views |

    The diversity of tumor cell responses to cyclin-dependent kinase 4/6 (CDK4/6) inhibition in breast cancer is a question not yet fully addressed. A recent study defines the effects of CDK4/6 inhibition on chromatin organization and shows that remodeling of the cancer cell epigenome mediates some of the key biological effects of these targeted therapy agents.

    • Antoni Hurtado
  • News & Views |

    Chronic pancreatitis is a risk factor for pancreatic cancer; however, the mechanisms underlying cellular susceptibility to oncogenic transformation are complex. A recent study reports a damage-associated progenitor cell state, controlled by the transcription factors KLF5 and members of the AP-1 family, that initiates tumorigenesis in mouse models of pancreatic cancer in which the proto-oncogene KRAS is altered.

    • Lindsay M. LaFave
    •  & Jason D. Buenrostro
  • Clinical Outlook |

    Recent preclinical and clinical research has led to exciting advances related to high-grade serous ovarian cancer, from examining its cellular origins to gaining insight into DNA-damage-repair mechanisms that may be leveraged for therapies. Furthermore, studies have demonstrated clinical benefit for inhibition of the polymerase PARP and modulation of the cell cycle, and have identified molecular features related to therapeutic response.

    • Michelle McMullen
    • , Katherine Karakasis
    • , Robert Rottapel
    •  & Amit M. Oza
  • Comment |

    Precision oncology trials based on cancer biomarkers have the potential to improve outcomes by guiding the optimal choice of therapies for patients. For this to be truly achieved, computational methods such as virtual molecular tumor boards, dynamic precision medicine and digital twins are needed to support cohort selection and trial enrollment at scale.

    • Subha Madhavan
    • , Robert A. Beckman
    • , Matthew D. McCoy
    • , Michael J. Pishvaian
    • , Jonathan R. Brody
    •  & Paul Macklin